Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb’s Opdivo approved for urothelial carcinoma in Europe

Bristol-Myers Squibb’s Opdivo approved for urothelial carcinoma in Europe

9th June 2017

Bristol-Myers Squibb has announced that the European Commission has approved its multipurpose cancer drug Opdivo in another new indication.

The therapy has been ratified for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after the failure of prior platinum-containing therapy, making Opdivo the first immuno-oncology agent approved in the EU for this condition.

This approval was based on positive findings from the CheckMate-275 study, which indicated that Opdivo can deliver strong response rates and enhanced survival prospects for this disease.

Bladder cancer is the fifth most commonly diagnosed cancer in Europe, with an estimated 151,000 new cases diagnosed per year. Urothelial carcinoma is the most common form, accounting for approximately 90 percent of cases.

Murdo Gordon, executive vice-president and chief commercial officer of Bristol-Myers Squibb, said: "With this second EU approval for Opdivo in as many months, Bristol-Myers Squibb is demonstrating our commitment to help address unmet needs for cancer patients."

Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world, with its clinical development programme having enrolled more than 25,000 patients to date.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801836697-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.